Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-05-18 | Dec-31-17 | Dec-31-16 |
| 10-K | 10-K | 10-K | 10-K | 10-K | 8-K | 10-K | 10-K |
Revenues: |
China Distribution and Technology Licensing Agreement | 48.6 | 46.9 | | | | | | |
International | 255.4 | 219.8 | 160.1 | | | | | |
Neuro | 347.7 | 338.7 | 292.6 | 331.7 | 294.3 | | 232.4 | 185.5 |
Vascular | 499.4 | 408.9 | 267.8 | 215.7 | 150.6 | | 101.3 | 77.8 |
Total revenues | 847.1 | 747.6 | 560.4 | 547.4 | 444.9 | 444.9 | 333.8 | 263.3 |
Revenue growth [+] | 13.3% | 33.4% | 2.4% | 23.0% | 33.3% | | 26.8% | 41.5% |
China Distribution and Technology Licensing Agreement | 3.6% | | | | | | | |
International | 16.2% | 37.3% | | | | | | |
Neuro | 2.7% | 15.7% | -11.8% | 12.7% | 26.6% | | 25.3% | 31.2% |
Vascular | 22.1% | 52.7% | 24.1% | 43.2% | 48.6% | | 30.3% | 74.1% |
Cost of goods sold | 311.9 | 272.2 | 222.2 | 175.4 | 152.4 | 152.4 | 116.6 | 92.5 |
Gross profit | 535.2 | 475.4 | 338.2 | 372.0 | 292.5 | 292.5 | 217.1 | 170.8 |
Gross margin | 63.2% | 63.6% | 60.3% | 68.0% | 65.7% | 65.7% | 65.1% | 64.9% |
Selling, general and administrative | 449.7 | 378.3 | 287.1 | 272.7 | 226.4 | 226.4 | 184.3 | 148.3 |
Research and development | 79.4 | 104.6 | 90.0 | 51.7 | 36.2 | 36.2 | 31.7 | 23.9 |
Equity in earnings | | | | | -3.1 | -3.1 | -1.4 | |
Other operating expenses | | | | | 30.8 | 30.8 | | |
EBITDA [+] | 30.4 | 8.9 | -26.1 | 55.6 | 2.2 | | 3.5 | 0.9 |
EBITDA growth | 241.3% | -134.2% | -146.8% | 2410.7% | -37.0% | | 271.3% | -84.0% |
EBITDA margin | 3.6% | 1.2% | -4.6% | 10.2% | 0.5% | -0.9% | 1.1% | 0.4% |
Depreciation | 15.1 | 13.5 | 11.8 | 7.1 | 5.1 | | 3.4 | 2.3 |
EBITA | 15.3 | -4.6 | -37.9 | 48.6 | -2.9 | -4.0 | 0.2 | -1.4 |
EBITA margin | 1.8% | -0.6% | -6.8% | 8.9% | -0.6% | -0.9% | 0.0% | -0.5% |
Amortization of intangibles | 9.2 | 2.9 | 1.1 | 1.1 | 1.1 | | 0.4 | |
EBIT [+] | 6.1 | -7.5 | -38.9 | 47.5 | -4.0 | -4.0 | -0.3 | -1.4 |
EBIT growth | -181.1% | -80.7% | -182.0% | -1301.8% | 1391.7% | | -80.4% | -132.3% |
EBIT margin | 0.7% | -1.0% | -6.9% | 8.7% | -0.9% | -0.9% | -0.1% | -0.5% |
Interest income | 0.1 | 0.9 | 1.3 | 2.9 | 3.0 | 3.0 | 2.7 | 2.3 |
Interest income | 0.1 | 0.9 | 1.3 | 2.9 | 3.0 | 3.0 | 2.7 | 2.3 |
Other income (expense), net | -2.3 | -3.9 | -0.3 | -0.2 | 2.6 | 2.6 | 0.1 | -1.8 |
Pre-tax income | 3.9 | -10.5 | -38.0 | 50.1 | 1.6 | 1.6 | 2.5 | -0.9 |
Income taxes | 5.9 | -13.1 | -18.8 | 3.1 | -4.4 | -4.4 | -3.6 | -15.7 |
Tax rate | 151.4% | 125.0% | 49.3% | 6.2% | | | | 1804.7% |
Minority interest | | -2.7 | -3.6 | -1.5 | -3.7 | -3.7 | | |
Net income | -2.0 | 5.3 | -15.7 | 48.5 | 12.6 | 6.6 | 10.7 | 14.8 |
Net margin | -0.2% | 0.7% | -2.8% | 8.9% | 2.8% | 1.5% | 3.2% | 5.6% |
|
Basic EPS [+] | ($0.05) | $0.14 | ($0.44) | $1.39 | $0.37 | $0.19 | $0.33 | $0.49 |
Growth | -136.8% | -132.7% | -131.5% | 277.4% | 13.4% | | -33.0% | 438.0% |
Diluted EPS [+] | ($0.05) | $0.14 | ($0.44) | $1.34 | $0.35 | $0.18 | $0.30 | $0.44 |
Growth | -137.9% | -131.8% | -132.9% | 282.3% | 14.9% | | -31.3% | 480.5% |
|
Shares outstanding (basic) [+] | 37.8 | 36.8 | 35.8 | 34.8 | 34.1 | 34.1 | 33.0 | 30.5 |
Growth | 2.9% | 2.8% | 2.9% | 1.8% | 3.5% | | 8.3% | 154.0% |
Shares outstanding (diluted) [+] | 37.8 | 37.9 | 35.8 | 36.3 | 36.1 | 36.1 | 35.3 | 33.5 |
Growth | -0.1% | 5.9% | -1.4% | 0.5% | 2.2% | | 5.5% | 135.4% |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|